MORRIS PLAINS, N.J., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Mr. Kenneth J. Zuerblis has been appointed to the Company’s Board of Directors. Mr. Zuerblis served as Chief Financial Officer and Senior Vice President of ImClone Systems Incorporated, prior to its 2008 acquisition by Lilly (NYSE:LLY). Previously, he was the Chief Financial Officer of Enzon Pharmaceuticals Inc (Nasdaq:ENZN).
